Randomized phase II study of 3 doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer
Cancer Science, 06/08/2012
Clinical Article
Inaji H et al. – TAS–108 at all dose levels was well tolerated and appeared to have no harmful effects in terms of the variables examined in this study. The authors conclude that the optimal dose of TAS–108 among the 3 doses is 40mg, once daily, for further studies.
